跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 8 条关于
“Relfydess”
全部
8
临床试验
0
药物
0
机构
0
资讯
8
去年
Galderma Showcases Latest Aesthetic Portfolio Data at IMCAS 2025, Highlighting Relfydess and Restylane Advances
8个月前
Galderma Presents Phase 3 Data on Relfydess Neuromodulator at TOXINS 2026, Demonstrating Superior Efficacy and Duration
去年
Galderma's Relfydess Shows Rapid, Long-Lasting Improvement for Frown Lines in Phase IIIb Trial
2个月前
FDA Issues Complete Response Letter to Galderma for RelabotulinumtoxinA Over Manufacturing Observations
上个月
Galderma Lifts Full-Year Guidance as H1 2026 Sales Surge 24.6% to $3.13 Billion
上个月
Global Botulinum Toxin Market Poised to Reach $29 Billion by 2035, Driven by Aesthetic Democratization and Expanding Therapeutic Indications
去年
RelabotulinumtoxinA Shows Long-Term Safety and Efficacy in Phase III Trial for Facial Lines
2个月前
The Next Era of Aesthetic Medicine: From Treatment Stacking to Regenerative Science